RCUS
Analyst says: show me the kidney cancer upside
HC Wainwright is leaning in on Arcus Biosciences after boosting its price forecast by 33%, from $32 to $45, while keeping a Buy rating on the stock. The thesis is pretty simple: if casdatifan can keep flexing in first-line clear cell renal cell carcinoma (ccRCC), the market opportunity gets a lot juicier.
Why the Street got more excited
Arcus has been talking up a broader development plan for casdatifan, aiming to make it a backbone therapy in 1L ccRCC. Translation: not just a niche add-on, but a drug with a shot at being part of the standard cocktail doctors reach for first.
The company is now enrolling a cohort in its Phase 1/1b ARC-20 study, with the goal of building enough evidence to kick off a Phase 3 study at the end of 2026. That’s still early-stage biotech territory — where the runway is long and the potholes are real — but it’s also where big upside narratives tend to start.
The Merck comparison is doing a lot of work
HC Wainwright is also pointing to differentiation versus Merck’s Welireg, saying casdatifan could be more potent with a stronger PD effect. That matters because biotech investors are basically always asking the same question: is this drug just another me-too, or is it actually meaningfully better?
A couple of things to keep in mind:
- The analyst’s new valuation bakes in casdatifan revenue from the broad 1L ccRCC opportunity
- The model also still includes the post-IO market, which remains a big piece of the story
- The catch: the program is early, and the analyst is only assuming a 30% probability of success in 1L ccRCC
Big picture
RCUS popped after the note, and for good reason: when a biotech analyst starts penciling in billions in peak sales, the stock usually perks up. But this is still a clinical-development story, which means the next big move depends on data, not just dreams and a louder-than-usual spreadsheet.